• About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
    • Registration
    • ICNMDigital Program
    • ICNMDigital Industry-Supported Symposia
    • CME Accreditation
    • Virtual Congress FAQs
    • Registration
    • ICNMD 2021 Preliminary Congress Agenda
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs
    • Related Events
    • Contact
    • Program at a Glance
    • Registration
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • Venue Information
    • Travel Information
    • Valencia Information
    • Contact
    • Past Congresses
MENU
  • About ICNMD
  • Past Congresses
  • Contact
  • About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
  • About ICNMD
  • Past Congresses
  • Contact
  • #ICNMD2021
  • Facebook
  • Twitter
  • Linkedin
  • About
    • About ICNMD
    • ICNMD2021 Committees
    • ICNMD 2021 Virtual FAQs (Frequently Asked Questions)
    • ICNMD 2021 FAQs
    • Related Events
    • Contact
  • Program
    • Program at a Glance
  • Sponsorship
    • Sponsorship Opportunities
    • Confirmed Supporters
    • Industry-Supported Symposia
    • ICNMDigital Program
    • Virtual Congress FAQs
    • CME Accreditation
    • ICNMDigital Industry-Supported Symposia
Get Tickets!

ICNMDigital Program

Access the ICNMDigital
Virtual Library
  • Registration
  • ICNMDigital Program
  • ICNMDigital Industry-Supported Symposia
  • CME Accreditation
  • Virtual Congress FAQs

Stay in the Know
Get the latest news on exciting speakers, workshops & learning opportunities at ICNMD 2021.

Subscribe for Updates

Tweets by ICNMD 2021

11 September
12 September
13 September
14 September

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
MUSCLE DISEASES
MUSCLE DISEASES
Scientific Session 01 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Marianne De Visser, The Netherlands

Inflammatory Autoimmune Myopathies
Prof Olivier Benveniste, France
30 Minutes

Genetic Therapies
Dr Kevin Flanigan, United States
30 minutes

Scientific Session 02 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Bjarne Udd, Finland

MYO-SEQ, Diagnosing Patients with LGMD
Prof Volker Straub, UK
30 minutes

Metabolic Therapies
Prof John Vissing, Denmark
30 minutes

Industry Supported Symposium 01 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 03 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Antonio Tascano, Italy

Novel Image Analysis to Assess Molecular Functionality of Dystrophin in Duchenne Muscular Dystrophy Clinical Trials
Mr Dominic Scaglioni, UK
20 minutes

A Dominant PYGM Mutation Causes a New Class of Glycogen Storage Diseases
Dr Jocelyn Laporte, France
20 minutes

Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
Sra Beatriz Llamusi, Spain
20 minutes

Industry Supported Symposium 02 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

MUSCLE DISEASES
  • Scientific Session 01 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Inflammatory Autoimmune Myopathies
    - Genetic Therapies
    10:00 - 11:00
  • Scientific Session 02 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - MYO-SEQ, Diagnosing Patients with LGMD
    - Metabolic Therapies
    11:30 - 12:30
  • Industry Supported Symposium 01 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 03 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Novel Image Analysis to Assess Molecular Functionality of Dystrophin in Duchenne Muscular Dystrophy Clinical Trials
    - A Dominant PYGM Mutation Causes a New Class of Glycogen Storage Diseases
    - Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
    14:30 - 15:30
  • Industry Supported Symposium 02 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
PERIPHERAL NEUROPATHIES
PERIPHERAL NEUROPATHIES
Scientific Session 04 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Peter Van Den Bergh, Belgium

Dysimmune Nodo-Paranodopathies
Dr Luis Querol, Spain
30 minutes

Painful Channelopathies
Prof Giuseppe Lauria, Italy
30 minutes

Scientific Session 05 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Dr Davide Pareyson, Italy

Charcot-Marie-Tooth and Related Neuropathies
Prof Mary Reilly, UK
30 minutes

Diabetic Neuropathy: Treatment and Costs
Dr Brian Callaghan, USA
30 minutes

Industry Supported Symposium 03 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 06 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Sessions Chair: Prof John England, USA

Combination of RNA-Interference and Gene Therapy to Treat Charcot-Marie-Tooth Type 2A
Dr Elena Abati, Italy
20 minutes

PDXK-Related Peripheral Neuropathy With Optic Atrophy. A New Treatable Disease
Dr Viorica Chelban, United Kingdom
20 minutes

De Novo Variants in POLR3B Cause Demyelinating Neuropathy, Ataxia, and Spasticity
Dr Djurdja Djordjevic, Canada
20 minutes

Industry Supported Symposium 04 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

PERIPHERAL NEUROPATHIES
  • Scientific Session 04 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Dysimmune Nodo-Paranodopathies
    - Painful Channelopathies
    10:00 - 11:00
  • Scientific Session 05 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - Charcot-Marie-Tooth and Related Neuropathies
    - Diabetic Neuropathy: Treatment and Costs
    11:30 - 12:30
  • Industry Supported Symposium 03 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 06 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Combination of RNA-Interference and Gene Therapy to Treat Charcot
    - Marie-Tooth Type 2A
    - PDXK-Related Peripheral Neuropathy With Optic Atrophy. A New Treatable Disease
    -De Novo Variants in POLR3B Cause Demyelinating Neuropathy, Ataxia, and Spasticity
    14:30 - 15:30
  • Industry Supported Symposium 04 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
NEUROMUSCULAR JUNCTION DISORDERS
NEUROMUSCULAR JUNCTION DISORDERS
Scientific Session 07 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Zohar Argov, Israel

Congenital Myasthenic Syndromes
Prof David Beeson, United Kingdom
30 minutes

Thymectomy
Dr Gil Wolfe, United States
30 minutes

Scientific Session 08 (11:30 CEST / 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Angela Vincent, UK

Immunoactive Drug Therapy
Prof Nils Erik Gilhus, Norway
30 minutes

Drugs Related Exacerbation
Amelia Evoli, Italy
30 minutes

Industry Supported Symposium 05 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 09 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Susana Quijano-Roy, France

Clinical Characteristics and Outcomes of Thymoma Associated Myasthenia Gravis
Mr Rodrigo Alvarez Velasco, Spain
20 minutes

Treatment Impact on Specific Symptom MG-ADL Domains Myasthenia Gravis Patients: Phase 2 Efgartigimod Study Analysis
Dr James Howard, United States
20 minutes

Prevalence and Associated Factors of Fatigue in the Dutch MG Population
Dr Martijn Tannemaat, Netherlands
20 minutes

Industry Supported Symposium 06 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

NEUROMUSCULAR JUNCTION DISORDERS
  • Scientific Session 07 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - Congenital Myasthenic Syndromes
    - Thymectomy
    10:00 - 11:00
  • Scientific Session 08 (11:30 CEST / 05:30 EDT / 02:30 PDT)
    - Immunoactive Drug Therapy
    - Drugs Related Exacerbation
    11:30 - 12:30
  • Industry Supported Symposium 05 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 09 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - Clinical Characteristics and Outcomes of Thymoma Associated Myasthenia Gravis
    - Treatment Impact on Specific Symptom MG-ADL Domains Myasthenia Gravis Patients: Phase 2 Efgartigimod Study Analysis
    - Prevalence and Associated Factors of Fatigue in the Dutch MG Population
    14:30 - 15:30
  • Industry Supported Symposium 06 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
MOTOR NEURON DISEASES
MOTOR NEURON DISEASES
Scientific Session 10 (10:00 CEST / 04:00 EDT / 01:00 PDT)
10:00 - 11:00

Session Chair: Prof Marianne De Visser, The Netherlands

New guidelines For the Design and Implementation of ALS Clinical Trials
Prof Leonard Van Den Berg, Netherlands
30 minutes

Advances in Genetics & Epigenetic of ALS
Dr Bryan Traynor, United States
30 minutes

Scientific Session 11 (11:30 CEST/ 05:30 EDT / 02:30 PDT)
11:30 - 12:30

Session Chair: Prof Benedikt Schoser, Germany

Therapeutic Considerations in SMA 2020: Who, When and How to Treat
Dr Richard Finkel, United States
30 minutes

Newborn Screening
Prof Laurent Servais, UK
30 minutes

Industry Supported Symposium 07 (13:00 CEST / 07:00 EDT / 04:00 PDT)
13:00 - 14:00

Sponsored Symposium
60 minutes

Scientific Session 12 (14:30 CEST / 08:30 EDT / 05:30 PDT)
14:30 - 15:30

Session Chair: Prof Enrico Bertini, Italy

A Longitudinal Natural History Study for Type 2 and 3 Spinal Muscle Atrophy
Ms Jesica Maria Exposito Escudero, Spain
20 minutes

Cervical Spinal Cord Atrophy: An Early Marker of Survival Time in Amyotrophic Lateral Sclerosis
Miss Virginia Reyes Garrido, Spain
20 minutes

Industry Supported Symposium 08 (16:00 CEST / 10:00 EDT / 07:00 PDT)
16:00 - 17:00

Sponsored Symposium
60 minutes

MOTOR NEURON DISEASES
  • Scientific Session 10 (10:00 CEST / 04:00 EDT / 01:00 PDT)
    - New guidelines For the Design and Implementation of ALS Clinical Trials
    - Advances in Genetics & Epigenetic of ALS
    10:00 - 11:00
  • Scientific Session 11 (11:30 CEST/ 05:30 EDT / 02:30 PDT)
    - Therapeutic Considerations in SMA 2020: Who, When and How to Treat
    - Newborn Screening
    11:30 - 12:30
  • Industry Supported Symposium 07 (13:00 CEST / 07:00 EDT / 04:00 PDT)
    13:00 - 14:00
  • Scientific Session 12 (14:30 CEST / 08:30 EDT / 05:30 PDT)
    - A Longitudinal Natural History Study for Type 2 and 3 Spinal Muscle Atrophy
    - Cervical Spinal Cord Atrophy: An Early Marker of Survival Time in Amyotrophic Lateral Sclerosis
    14:30 - 15:30
  • Industry Supported Symposium 08 (16:00 CEST / 10:00 EDT / 07:00 PDT)
    16:00 - 17:00

Click here to view disclosure information for individuals involved in the educational programming for ICNMDigital.

For the list of virtual industry-supported seminars (non-accredited), please visit the Virtual Industry-Supported Symposia page.



  •  

    The ICNMD is organized on behalf of the Applied Research Group on Neuromuscular Diseases of the World Federation of Neurology.
  • Stay Connected

    Keep up to date with Conference News & Alerts.
    Sign Up

     

    #ICNMD2021

  • ICNMD2021 Conference Secretariat
    ICS International Conference Services LTD (ICS)
    300 – 1201 West Pender Street
    Vancouver, BC, Canada V6E 2V2
    P: [+1] 604 681 2153
    E: icnmd2021@icsevents.com
    Web: icnmd.org
© 2021 International Congress on Neuromuscular Diseases | Privacy Notice

Stay Up to Date!
Receive the latest information about the International Congress on Neuromuscular Diseases by entering your information below.
Thank you! We look forward to connecting soon.
Click here to close this windows
Whoops, looks like there was an issue with one of the fields above - please review above.
X